Duck Creek Technologies (NASDAQ: DCT) stock is down 64% year-to-date but is rising in pre-market trading. The company went public in August 2020 and coasted along until September 2021, when it began a steep decline. Today DCT has a $1.4bn market cap.

The company is due to report its quarterly and full fiscal year earnings on October 12 after the market close. FactSet analyst estimates provide an EPS consensus of $0.10 and a sales consensus of $295.27m for the Fiscal Year Ending August 2022.

#What Does Duck Creek Technologies Do?

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry.

People buy insurance as financial protection against fire, flooding, hurricanes etc. When it comes to Property and Casualty (P&C), this insurance covers homes, contents, cars, boats, motorcycles, water skis and more.

Duck Creek has evolved from being a traditional software provider to offering cloud-based solutions, which include bi-weekly software updates.

Many modern insurance systems are built on the Duck Creek Technologies platform. It serves insurance providers and carriers, and Duck Creek is at the heart of generating insurance quotes, providing bills, and providing a claims system.

Indeed, Duck Creek Technologies enables the insurance industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations.

Company products include Duck Creek policy, billing, claims, insights, ratings, distribution management, digital engagement, reinsurance management, and Duck Creek industry content.

Duck Creek Technologies was founded in 2000, is headquartered in Boston, Massachusetts and serves customers worldwide.

#SBS Partnership

On October 10, Duck Creek Technologies announced a collaboration with SBS Insurance Services as one of its newest integration accelerators.

This partnership will allow Duck Creek customers a seamless digital journey. They'll be able to achieve a one-touch, same-day contents claim settlement via the Duck Creek Content Exchange integrated with SBS's Digital Household Contents Validation systems.

Shreyas Vasanthkumar, Duck Creek's Managing Director, Europe, the Middle East and Africa (EMEA), said:

We are thrilled to partner with SBS and expand further our footprint in the European market by offering SBS’ reliable content solutions to our customers, 

This partnership will help us meet the needs of our customers in a seamless and timely manner as the solution provides quick property replacement, which is a huge priority for insureds when they file a claim following an incident.

Sean Crowley, CEO of SBS, said:

SBS has been an innovator in the household contents market for over two decades, we are delighted to collaborate with Duck Creek – integrating P&C claims into one seamless claims journey, supported by award-winning technology and decades of expertise which SBS is synonymous with.

#How Does Duck Creek Technologies Make Money?

Duck Creek Technologies makes money from:

• Selling its hosted software services (SaaS) under subscription arrangements. 

• Software license revenue is derived from selling perpetual and term license arrangements to customers.

• Sales of maintenance and support services. These include telephone and web-based support, software updates, and rights to unspecified software upgrades on a when-and-if-available basis during the maintenance term.

• Sales of professional services. These primarily relate to implementing the company's SaaS offerings and software licenses.

The majority of Duck Creek's revenues come from the United States.

#DCT Stock Financials

DCT stock has a forward price-to-earnings ratio (P/E) of 87, which makes it look overvalued unless it can achieve impressive earnings growth. Its price-to-book-value (P/BV) is 1.98. DCT stock does not offer a shareholder dividend.

Over the past year, DCT stock has traded between $10.54 and $46.75. Today it trades at around $10.95. Year-to-date, the Duck Creek Technologies Inc stock price is down -64%, while the S&P 500 is down -25.18% over the same period.

FactSet analysts have a consensus Overweight rating on DCT stock with a target share price of $18.25.

#Revenue Agreements with Investors

As of May 31, 2022, Accenture held 16% of the company's outstanding shares of common stock.

Duck Creek Technologies provides certain professional and software maintenance services to end customers as a subcontractor to Accenture as part of its typical revenue-generating arrangements.

The company also engages Accenture to provide professional services as part of its typical revenue-generating arrangements.

#Duck Creek Technologies Growth Potential and Risks

Duck Creek's growth strategy focuses on developing its SaaS solutions and selling into new markets or penetrating existing ones. A part of Duck Creek Technologies' growth strategy is to bring AI into the mix. This should improve the user experience while improving search capabilities.

It also wants to broaden its scope of enterprise offerings to increase its customer footprint and overall value proposition.

Duck Creek currently serves a small percentage of the available market, so there is considerable potential for earnings growth. However, it faces competition, and many big insurers invest in digital engagement and streamlined systems.

The insurance business is complex, and regulations differ across 50 states. This complexity means the insurance industry has a high barrier to entry, making it difficult for newcomers to disrupt.

Meanwhile, insurance innovation is accelerating with the adoption of new technologies.

Duck Creek's competitors include Guidewire Software (NYSE: GWRE), Sapiens International Corporation (NASDAQ: SPNS), EIS Group, Insurity, Majesco, RGI and Prima Solutions.

#Is DCT Stock a Good Investment?

Unfortunately, Duck Creek Technologies has a history of losses, making investors wary of the stock. But it has been increasing sales year-over-year for the past five years.

The company is trading on a price-to-sales multiple of 5, which is high, but in line with some SAAS businesses in the space. 

Investors will be looking for an earnings beat and promising signs of growth in today's earnings call.

#If you enjoyed our Duck Creek Technologies coverage, you might be interested in our recent Daily Stock Watch articles or our IPO coverage.

Copper prices have pulled back this year, but as supplies dwindle around the world, some investors are betting a price surge is set to come. Meanwhile, Vale (NYSE: VALE) seems to agree. The iron ore mining company is reportedly getting set to spin off its base metals business, comprising copper and nickel, in a bid to capitalize on its potential growth trajectory.

According to a Reuters report, Vale’s CEO Eduardo Bartolomeo said the company is reconsidering a near-term spinoff of its base metals business and eventual public listing.

Vale originally planned to sell all or part of the segment but now hopes to build the business as big as Vale is today and take it public. Bartolomeo made the comments at the FT Mining Summit.

Bartolomeo noted there is "huge growth" in base metals, whereas iron ore is a mature business.

#What Does Vale SA Do?

Vale is the world's largest iron ore miner and, along with BHP and Rio Tinto, is one of the largest diversified miners. 

Vale SA produces and sells iron ore, pellets, manganese, alloys, gold, nickel, copper, kaolin, bauxite, alumina, aluminum, and potash.

The company is based in Brazil, where it owns and operates railroads and maritime terminals. Vale also has operations in Australia, Canada, Oman, Indonesia, Japan, China and Malaysia.

In recent weeks, Vale has become the first of the world’s biggest mining companies to test 100% electric 72-ton trucks as it aims to reduce its emissions. These trucks will be used in its Indonesian mines.

#How Does Vale Make Money?

Vale makes most of its money from its bulk materials division, primarily from selling iron ore and iron ore pellets, with manganese and coal also contributing.

The company’s base metals division brings in less cash but, as a spin-out, has longer-term potential. Its base metals segment includes nickel mines and smelters, along with copper.

#Copper Outlook

Copper and nickel are key components of green tech, including batteries for electric vehicles, solar panels and wind turbines.

Copper has been in a bear market this year, and China’s zero-COVID policy has compounded this by reducing demand. With Xi Jinping securing another term, there are debates about when demand from China will return.

Nevertheless, the big-picture outlook for copper remains strong if the energy transition is to remain on track.

Yesterday Bloomberg reported that China’s multi-billion-dollar bonded copper stockpiles are at their lowest level in decades. JPMorgan Chase & Co. and ICBC Standard Bank Plc have halted new business in the region, and several sources believe the cash for copper trade to be dead for now, thanks to the global fall in demand.

But given copper’s role in the global energy transition, those investors with a longer time horizon see the likelihood of copper price spikes ahead.

If or when China reopens and resumes purchasing, copper prices could skyrocket, given China’s current stock depletion.

David Lilley, chief executive of hedge fund Drakewood Capital Management Ltd, said:

The physical market is so tight, it’s like a room full of gunpowder — any spark and the whole thing could blow, [Without the Shanghai bonded inventory], we are living without a safety net.

Back in 2011/12, China’s bonded copper stockpile totaled around a million tons of copper. It’s now around 30k tons.

The price of copper has plummeted in recent months, but the market is tight in China, and traders are paying a premium for immediate supplies.

But it’s not just China. Years of underinvestment in copper mining, ESG mandates, and regulatory crackdowns have led to the depletion of copper supplies worldwide.

With this dearth in supplies, copper buyers are attempting to secure longer-term deals to ensure their future supplies. Chilean miner Codelco recently signed copper contracts for three and five-year deals. Codelco is owned by the Chilean government.

#VALE Stock Financial Metrics

VALE reports quarterly earnings on October 27. FactSet analyst estimates provide an EPS consensus of $0.56 and a sales consensus of $10.14bn. 

Over the past year, VALE stock has traded between $11.16 and $21.29. Today it trades at around $13.65. Year-to-date, the Vale stock price is down -1%, while the S&P 500 is down -20.05% over the same period.

FactSet analysts have a consensus Overweight rating on VALE stock with a target share price of $17.06.

VALE stock has a price-to-earnings ratio (P/E) of 3.21. Its price-to-book-value (P/BV) is 1.77. Better still, VALE stock comes with a whopping dividend yield of 10.46%.

In 2021, the company reported annual sales of $54.39bn and net income of $24.7bn. This is projected to slip to revenues of $43.94bn and profits of $15.32bn in 2022.

#Vale Growth Potential and Risks

Vale is a $64bn company with a fixed presence in several international jurisdictions. This makes it susceptible to forex fluctuations. Its commodities are in long-term structural demand, but short term, it faces multiple headwinds.

Inflation is hitting Vale's bottom line, as are falling commodity prices. If geopolitical circumstances worsen or China’s lockdowns continue far into the future, commodity prices could have much further to fall. 

But the opposing view is that demand will far outpace supply, and Vale is positioning to capitalize in the future.

#Is VALE Stock a Good Investment?

Vale is shareholder friendly. The company has been buying back shares and reducing debt while paying a generous dividend. Its financial metrics point to an undervalued stock, and the Vale share price is closer to its 52-week low than its high, making it attractive to investors.

Nevertheless, Vale’s future returns are highly dependent on commodity pricing, which is cyclical. That’s why investing in mining stocks is risky and only for investors who understand the business and believe in a growing demand for the underlying assets.

Vale's quarterly earnings this week will be worth watching to hear how it's coping with inflation and suppressed commodity prices.

Meanwhile, alternative copper mining stocks include Freeport-McMoRan (NYSE: FCX), BHP Group (NYSE: BHP), and Glencore (LON: GLEN).

#If you enjoyed our Vale coverage, you may be interested in our recent Daily Stock Watch articles or our IPO coverage.

Piper Sandler raised its target on AXNX share price to $84 from $82. It sees several growth drivers evident, including increasing therapy awareness driven by the company's efforts in direct-to-consumer marketing.

Axonics (NASDAQ: AXNX) is a global medical technology company developing and commercializing novel products to treat bladder and bowel dysfunction.

#What Does Axonics Do?

According to Bloomberg, Axonics, Inc. operates as a medical technology company. The company focuses on designing, developing, and commercializing innovative and minimally invasive sacral neuromodulation solutions used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Axonics serves patients worldwide.

The company offers users an Axonics Therapy trial using a disposable device, and for those that want to continue, there's a discrete implant. This is operated with remote control. It claims to help restore the connections between the brain and bladder or bowel to give users a better quality of life. 

The company is shifting its product focus from a rechargeable product to the F15, its new non-rechargeable device, also known as the primary cell, which has a higher gross margin. It can also potentially last around 20 years in the body, far exceeding any previous products.

It also has an FDA application for a new rechargeable device with a recharging interval of one hour every six months. 

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy-to-use, safe, clinically effective therapy.

Additionally, the company acquired Bulkamid, a best-in-class urethral bulking hydrogel, last year. Bulkamid provides safe and durable symptom relief to women with stress urinary incontinence (SUI).

Axonics is creating awareness of the profoundly embarrassing and personal issues it can help with via direct-to-consumer advertising on television and other media.

During a September fireside chat with Wells Fargo, Axonics CEO and Director Ray Cohen was very upbeat in the company's outlook. The team is building consumer awareness, improving its product offering and witnessing the market grow at pace.

Ray Cohen, CEO and Director of Axonics, commented:

If we go back to 2019 and we look at what's happened… 2019 to 2021, what we see is that's running at about a 15% compounded annual growth rate (CAGR), which is precisely what we've said that we thought would happen.

Danny L. Dearen, President & Chief Financial Officer, Axonics Modulation Technologies, Inc., said:

Things are going quite well. We have good momentum in the business, and we feel good about where we are today and the balance of the year. 

#How Does Axonics Make Money?

Axonics makes money selling its recharge-free F15™ SNM implantable stimulator, its r-SNM system, and Bulkamid. 

Before Q4 2019, Axonics derived revenue only from its international operations in select markets, including England, the Netherlands and Canada. 

Beginning in February 2021, with the acquisition of Contura Ltd, Axonics markets Bulkamid, a urethral bulking agent, to treat female stress urinary incontinence (SUI). And from March 2022, with the FDA approval of the company's long-lived, recharge-free F15™ SNM implantable stimulator, Axonics now markets and sells the F-15 recharge-free system to customers in the United States in addition to the existing r-SNM system. The new recharge-free system is protected by intellectual property based on company-generated innovations.

During the first half of 2022, Axonics brought in $117.4m in net revenue, compared to $80.2m in the first six months of 2021. 

Axonics' clinically proven products are offered at hundreds of medical centers across the US and abroad. Reimbursement coverage is well established in the US and is a covered service in most European countries.

#AXNX Stock Financials

Axonics has a $3bn market cap, and its share price is up 392% since going public in 2018.

Gross margins for Q2 came in at 72.5%. It is modeling the second half of the year on gross margins of 69%, which it hopes will account for any margin pressures on paying up for inventory. It has been overpaying to combat supply chain issues and keep things moving. 

Axonics raised its 2022 guidance on its Q2 call to $253m from prior revenue guidance of $238m, which represents growth of 40% compared to 2021.

Over the past year, AXNX stock has traded between $38.41 and $79.92. Today it trades at around $74. Year-to-date, the Axonics stock price is up by 26.32%, while the S&P 500 is down by -22.29% over the same period.

FactSet analysts have a consensus Buy rating on AXNX stock with a target share price of $82.37.

#Axonics Growth Potential and Risks

The addressable market is growing. When Axonics began discussing this in 2018, the US market was around $525m. Today it is about $750m, according to its data modeling.

Overactive bladder affects an estimated 87 million adults in the US and Europe, and an additional 40 million adults are estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the US alone.

The company is actively pursuing a direct-to-consumer marketing campaign and TV advertising.

The company says around 7% of its website visitors are filling out a symptom survey, with around 42k captured so far. The company reaches out to those interested in being matched with a provider to make the connection.

In its Q2 earnings call, Axonics indicated that COVID-19 deferrals, procedure slowdowns and staffing shortages did not impact its Q2 results. However, it did experience some supply chain challenges and higher costs for certain components. 

Cohen is still optimistic that the future looks rosy as the reopening is well underway and the Axonics procedures are relatively quick, so they don't tend to be impacted by staffing shortages.

Supply chain issues continue, but the company can pay up to overcome this. It is now building up an inventory supply and is getting closer to the ideal position it wants to be in. Plus, it is looking ahead and planning inventory build and ramp for 2024.

#AXNX Competition

Medtronic (NYSE: MDT) is Axonics' primary competitor, and both heavily focus on advertising and search engine optimization. Medtronic currently sells around seven of every ten devices today, but Axonics is taking market share.

Medtronic's InterStim X is its new non-rechargeable device with an 8-to-10-year life span. Axonics F15 has double the longevity with a potential 17-to-22-year life span. Also, Axonics' F15 is 30% to 40% smaller than the Medtronic competitive device.

#Is AXNX Stock a Good Investment?

Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

The company's goal is to achieve a 50.1% market share in a $1.5bn market. Whether it can achieve that remains to be seen.

Axonics is a speculative investment, particularly as overall market conditions are bearish. However, healthcare is a defensive sector, and this is a market with a clear need for Axonics' products.

#If you enjoyed our Axonics coverage, you might be interested in our recent Daily Stock Watch articles or our IPO coverage.

Our third quarter results demonstrated progress against our new operating strategy. We delivered record recurring revenue, a strong rebound of platform placements, gross margin improvement, and cash burn in line with our plan,

- Dr. Siddhartha Kadia, CEO of Berkeley Lights.

Biotech stocks have fallen out of favor, and investors are nervously awaiting an opportunity to buy the dip. Today, Berkeley Lights (NASDAQ: BLI) trades at $3, down 84% year-to-date and $100 lower than its multi-year high in December 2020. So, is BLI a biotech stock worth a closer look or could it continue to plummet? Let’s wade in. 

Are Biotech Penny Stocks Worth Investing In?

#What Does Berkeley Lights Do?

Scientific researchers use the Berkeley Lights platform to find the best cells for the job in a fraction of the time and cost of traditional methods. Berkeley Lights’ technology works with thousands of cells simultaneously, rapidly speeding up workflow. It records cell behavior and links to genetic information in real-time, thus helping develop and commercialize biotherapeutics and other cell-based products.

The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel. It can also deliver the live biology customers desire in the form of the best cells. It is a fully integrated, end-to-end solution comprising proprietary consumables, including Berkeley’s OptoSelect® chips, reagent kits, advanced automation systems, and application software.

The company developed its Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale and to establish an industry standard for its customers throughout its cell-based product value chain.

While Berkeley Lights is based in the United States, it has subsidiaries in the United Kingdom, China and Singapore.

#Q3 Highlights

Berkeley Lights Inc (BLI) reported its quarterly earnings on November 8. FactSet analyst estimates provided an EPS consensus of -$0.32 and a sales consensus of $21.58m. BLI met the consensus estimates with actual EPS of -$0.32 and slightly missed sales estimates with revenues of $21.4m.

• Total Revenue: $21.4m (-12% Y/Y, +12% Q/Q)

• Record Recurring Revenue: $7m (+48% Y/Y, +18% Q/Q)

• Gross Margin: 70.2% (+6.8% Y/Y, +2.7% Q/Q) 

#Forward Guidance

Berkeley Lights expects full-year 2022 revenue to be approximately in line with 2021 full-year revenue. 

Dr. Siddhartha Kadia, CEO of Berkeley Lights, said:

We are well on our way to transforming Berkeley Lights from a technology platform company into a growing, profitable, and sustainable life sciences tools and services company. We will continue to advance important changes to our business as we close out this year and lay a strong foundation for the immense opportunities ahead of us.

Berkeley Lights is expected to provide guidance for 2023 and insight into partnership opportunities and gross margin expectations in its Q4 earnings call.

#BLI Stock Financial Metrics

BLI stock has a price-to-book-value (P/BV) of 1.2. It does not offer shareholders a dividend.

Over the past year, BLI stock has traded between $1.82 and $26.75. Today it trades at around $3.09. Year-to-date, the Berkeley Lights Inc stock price is down -83.96%, while the S&P 500 is down -21.85% over the same period. 

#Analyst Ratings

Seven FactSet analysts have a Hold rating on BLI stock, with a target share price of $10.25.

#Berkeley Lights Corp Growth Potential and Risks

Berkeley Lights is taking a new approach to its growth strategy to better fit progressing in challenging economic times. The company confirmed it ended its collaboration agreement with Ginkgo Bioworks (NYSE: DNA) in early September as it ‘no longer supports its profitability goal.’ Meanwhile, Berkeley Lights confirmed that its collaboration agreements with Thermo Fisher Scientific, Bayer Crop Sciences and Vestaron are going very well and at different stages of completion.

Berkeley Lights is introducing a more flexible configuration and pricing strategy with a higher recurring revenue growth model. It is on track to launch the first of several application-specific Beacon system models early next year. 

While currently focused on assisting clients in the areas of AAV gene therapy and TCR discovery (virus and cancer detection), the company also serves some clients in the agrochemicals space.

The company may also consider M&A opportunities to expand its total addressable market. 

In terms of providing leverage to our current cost structure, we are looking at consolidation opportunities that will enhance our commercial infrastructure or drive significant R&D and G&A synergies.

During its Q3 earnings call, Mehul Joshi, CFO of Berkeley Lights, noted that even though capital expenditure budgets are being scrutinized and sales cycles are being extended, new customers are still very interested in the products and services Berkeley Lights has to offer. That’s reassuring to hear. 

Furthermore, the company has been in discussions with 100 potential gene therapy clients, so it is hopeful for positive returns from this engagement further down the line. Indeed, Berkeley Lights has validated with several customers that its platform can rapidly isolate and recover functional TCR sequences from patients who received personalized cancer vaccines. Therefore, its partnerships and services team is actively exploring commercial partners interested in this significant opportunity. 

#Is BLI Stock a Good Investment?

Operationally, Berkeley Lights is moving in the right direction, aiming to become a profitable life sciences company. Its Q3 net losses rose 5% Y/Y but fell 16.2% Q/Q. Recurring revenues growing is a good sign, but partnership revenues have been declining, which is less encouraging.

With the markets currently in a phase of uncertainty and inflation weighing on margins, share price volatility is to be expected, particularly in more speculative areas of the market, such as biotech and penny stocks.

For investors interested in BLI stock, it may be worth waiting for further insight from its Q4 and full-year earnings report, which should give more color to its future projections. 

#If you enjoyed our Berkeley Lights Corp coverage, you might be interested in our Spatial Computing stocks article.

Applied Digital Corporation (NASDAQ: APLD) stock is down 92% YTD as investors become wary of the crypto space. So, are blockchain and crypto mining stocks doomed or is this the perfect time to buy the dip? Read on for some analysis of APLD stock.

#What is Applied Digital (Applied Blockchain)?

Applied Digital, which recently changed its name from Applied Blockchain, Inc, designs, develops and operates next-generation datacenters across North America. The company provides digital infrastructure solutions to the rapidly growing high-performance computing (HPC) industry.

High-profile crypto companies that Applied Digital counts as clients include Bitmain, F2Pool, Marathon (NASDAQ: MARA), and GMR. 

The company went public via IPO in April 2022, at $5, with a float of nine million shares. Today Applied Digital Corp has 97.4 million shares outstanding and a share price of $1.94.

#Distressed Crypto Assets Fund

Applied Digital Corp recently launched an independent fund aimed at acquiring distressed cryptocurrency assets. The fund and its assets, which may include mining hardware and digital infrastructure assets, will be jointly managed by a newly formed entity, Highland Digital, a 50/50 joint venture between Applied Digital and GMR (a customer of Applied Digital).

The independent fund is targeting raising capital of up to $100m from outside investors.

Applied Digital Chairman and CEO Wes Cummins, said:

The creation of this fund and associated joint venture again demonstrates our creativity and strong industry relationships that position us to capitalize on this volatile market,

We have proven ourselves as a leading next-generation datacenter operator and hosting partner and look forward to deepening our partnership with GMR to take advantage of the opportunities we are seeing on a weekly basis.

Cummins believes any successful acquisitions by Highland Digital could create opportunities for Applied Digital to grow its hosting customer base. Applied Digital doesn’t plan to issue equity to raise capital for the fund.

Furthermore, APLD's infrastructure knowledge and GMR’s in-depth experience in managing mining hardware through cryptocurrency market cycles present a promising combination. Indeed, this could ensure they're in an excellent position to take advantage of the current distressed environment.

#APLD Stock Financials

Applied Digital will report its next quarterly update in February 2023. FactSet analyst consensus expects EPS of -$0.07 and sales of $12m. 

The company has a forward P/E of 5.5 (what is a P/E ratio?) and a P/BV of 2.6.

Sales in the fiscal year 2022 exceeded $8.5m. In Q3, 2023, sales exceeded $6.9m, and FactSet estimates for full-year 2023 come in around $105.3m. However, the company will not be providing sales guidance for its next two quarters as it is unclear when it will energize its new facilities.

#APLD Stock Growth Potential and Investment Risks

Any stock linked to the crypto market appears inherently risky as the industry falls out of favor. However, APLD has three things going for it. It doesn’t directly mine for crypto, it is focused on a diversified customer base, and its digital infrastructure is used by big industry names.

Next-generation datacenters have widespread appeal as tech companies vie for fast speeds and security. Therefore, the company’s digital infrastructure solutions are likely to appeal to the rapidly growing HPC industry.

Cryptocurrency-related stocks are extremely volatile and may be affected by external factors such as financial, regulatory or geopolitical events. Indeed, macroeconomic conditions suggest we’re slipping into a Bitcoin winter. 

Nevertheless, when one company goes bankrupt, the remaining competitors can bid for distressed assets. This is something Applied Digital has its eye on and is always on the lookout for additional sites with good power supply.

As the industry is undergoing a period of stress, Applied Digital is exposed to counterparty risk through its associations with its customers, including Bitmain and Marathon. Bitmain operates from its North Dakota site, as do F2Pool and GMR.

In its recent earnings call, Cummins stated that Marathon is one of the best counterparties, if not the best of the publicly-traded miners in the industry. That’s because it has a relatively clean balance sheet and no imminent debt repayments due.

Applied Digital purchases power and leases out its HPC applications and hosting services to customers. It is building a 500MW facility for Bitcoin mining while also aiming to attract HPC customers to diversify its client base and keep cash flowing. It also hopes to scale its GPU-based machine-learning application over the next year or two.

While Applied Digital doesn’t currently have any spare capacity to offer, it is actively seeking capacity from other customers to better serve the industry. Furthermore, it is focused on obtaining ultra-low-cost digital infrastructure for its HPC offerings.

#Is APLD a Good Investment?

Stocks operating in the crypto landscape are inherently linked to the price of Bitcoin. Therefore, when the Bitcoin price falls, it’s likely the APLD share price falls too, and vice versa when the price of Bitcoin rises.

Applied Digital is a risky stock, but one that is making money and has a bit of a buffer against the volatility of the crypto industry. It could also potentially benefit from increased demand for hosting amid constrained supply.

#Applied Blockchain in London

There is another company named Applied Blockchain, which could cause you confusion. The London-based Applied Blockchain is headed by founder Adi Ben Ari. This Applied Blockchain is a Web 3.0 development company that builds blockchain solutions to bridge the gap between Web 2.0 (where we are now) and Web 3.0 (where we want to be). 

The fundamental attraction of blockchain technology is that it can bring technical efficiency in a decentralized way that provides trust and security. This is what entices people to blockchain technology and is the reason there are still many blockchain enthusiasts despite the controversies surrounding Bitcoin and the recent collapse of FTX. 

Applied Blockchain claims to be building the necessary tech that will bridge this gap and enable a bright future for blockchain adoption.

It has a team of 100 developers, mainly based in London, with a presence in Portugal. Its customers are based all over the world, and several are in the US. Applied Digital recently worked with Ledger to implement Ethereum into the Ledger product. APMD has also worked with some well-known traditional companies, including Intel, Shell, Vodafone, Lloyd’s Register and the United Nations.

#Check out our recent articles:

State of the ARKK: Should You Invest in ARK Innovation ETF?

Is Amazon Still a Good Investment?

Top LiDAR stocks to invest in

Is Tesla a good stock to buy? 

#If you liked our APLD Stock coverage, why not read our Top Tin Stocks next?

Kymera Therapeutics (NASDAQ: KYMR) has seen its share price climb by more than 20% on Wednesday following positive clinical test results.

The company announced positive clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 clinical trial. The trial involved patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). While the latter is a common form of eczema, the former is a long-term condition that causes abscesses and scarring on the skin.

Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies. The Initial Phase 2 clinical trial of KT-474 will investigate its potential in HS and AD, with the first study initiated in 2023.

Kymera Founder, President and CEO Nello Mainolfi, commented:

“This is a pivotal moment for Kymera and for the field of protein degradation. Kymera was founded to harness the enormous potential of targeted protein degradation and bring more effective therapies to patients.

“We believe that, for the first time, we have demonstrated clinical impact of a degrader, KT-474, outside of oncology and in complex inflammatory diseases such as HS and AD. We have also demonstrated the superior clinical potential of an IRAK4 degrader over a small molecule inhibitor, validating our platform and target selection strategy.”

But does the latest news make KYMR stock a Buy?

#What is Kymera Therapeutics?

Kymera Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. 

The company says its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases.

The business' team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small-molecule protein degraders with potent activity against a broad range of disease indications.

The business’ treatment candidates include KT-474, KT-413 and KT-333, which are each in the first phase of clinical trials and target a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

#KYMR Stock Financials

The company’s most recent earnings showed it had achieved collaboration revenues of $9.6m for the three-month period that ended on 30 September. This is a drop from $20.3m in the same period 12 months prior.

While revenues have declined, operating expenses have been heading in the opposite direction. They jumped from $49.0m to $54.4m over the same period, resulting in operational losses climbing from $28.6m to $44.9m.

This meant net losses per share for the period came in at $0.79, deeper than the $0.56 loss achieved in the same period 12 months prior.

The business had cash, cash equivalents and marketable securities of $595.6m at the end of the period. 

KYMR stock had a price-to-sales ratio of 29.48 and a price-to-book value of 2.77. These compare with respective average ratios of 9.17 and 8.38 for biopharmaceutical stocks, according to CSIMarket. These paint a mixed picture of the stock, potentially framing it as overvalued.

At the time of writing, KYMR stock has dropped by 51.82% over the year to date. The last 12 months have seen its share price hit a high of $66.45 and a low of $13.15.

#KYMR Growth Potential

The market opportunity for treatments for the conditions targeted by Kymera is sizeable. There were global drug sales of $5.76bn for AD in 2021, while HS led to $1.11bn. Indeed, total global drug sales for the Th1-Th17 and Th2 diseases targeted by the company’s treatments under development saw combined sales of approximately $150bn in 2021.

Of course, Kymera getting a significant slice of this opportunity relies on its therapies making an impact.

#KYMR Investment Risks

The primary risk with a company such as Kymera is that its pharmaceutical candidates will not make it to the commercial stage, due to clinical trial difficulties and funding issues, or will fail to have a meaningful impact when they do. With a business like Kymera, which is at a particularly early stage, this risk is amplified.

On the other hand, the latest announcement will buoy investors who may have been spooked by the possibility of another risk earlier this year. That’s because Sanofi appears to have committed to working with Kymera on its lead treatment candidate into phase 2 testing.

There had been concerns that Kymera was pivoting away from KT-474 or that the project would be dropped by Sanofi. However, it seems that these concerns can be shelved for now. The loss of heavy-hitting strategic collaborators like Sanofi, Vertex and the Leukemia & Lymphoma Society would be damaging for KYMR.

#Is KYMR Stock a Good Investment?

Investing in a business so far from commercialization is always a major risk. There are a wealth of hurdles the company has yet to negotiate before it will start returning significant revenues.

On the bright side, the company is in a very secure position financially, with a runway of years ahead of it. This is necessary, given the early stage of clinical development at which even its most progressed candidates sit.

Stocks like KYMR are not attracting huge investment in the current climate, but the business’ significant funding, large addressable market, strategic partnerships and diverse roster of treatment candidates mean it has the potential to perform well in the long term.

The 18 analysts listed by the Wall Street Journal who cover the stock offer a rating of Overweight, along with an average price target of $53.94.

#Check out our recent articles:

Who is Steve Wozniak?

State of the ARKK: Should You Invest in ARK Innovation ETF?

Is Amazon Still a Good Investment?

Top LiDAR stocks to invest in

#If you enjoyed this article, why not check out more Daily Stock Watch analysis?

ESSA Pharma Inc (NASDAQ: EPIX) has seen its share price tumble by more than 30% before the market open after reporting patient recruitment issues with one of its clinical trials.

The business announced that Janssen Research and Development is suspending enrolment into the Phase 1 clinical study of the company’s EPI-7386 treatment candidate for patients with metastatic castration-resistant prostate cancer.

David Parkinson, CEO of ESSA, commented: 

"While we are disappointed that Janssen will not be completing this study, we thank Janssen for the conduct of the study to date and the patients who participated in the study.

"We are encouraged by the favorable safety, pharmacokinetic and initial clinical activity in these patients as these data further support the data generated in the EPI-7386 combination study with enzalutamide that ESSA is conducting.” 

Even so, the suspension of enrolment seems like a significant blow to ESSA Pharma. But is EPIX stock a good investment?

#What is ESSA Pharma?

ESSA Pharma is a clinical stage pharmaceutical company, which focuses on developing novel and proprietary therapies for the treatment of prostate cancer. 

It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.

The company has collaboration agreements with Caris Life Sciences, Bayer Consumer Care AG, Janssen Research & Development and Astellas Pharma.

ESSA Pharma was incorporated in 2009 and is headquartered in Vancouver, Canada.

#EPI-8207

Today’s swing in share price is the stock’s second major movement in less than a week, with EPIX rocketing on 26 October after the company announced strong pre-clinical data for its EPI-8207 treatment candidate.

ESSA reported that the candidate showed “robust potency degrading androgen receptors, including androgen receptor splice variants and clinically relevant androgen receptor mutants that can potentially drive disease progression in patients with castration-resistant prostate cancer”.

While this news led to excitement among investors, the difficulties reported today pertaining to ESSA’s lead treatment candidate could undo the resulting stock price gains.

#How Does ESSA Pharma Make Money?

As the company is in the clinical stage, it has yet to earn significant revenues from the sale of any products.

#EPIX Stock Financials

The year to date has seen EPIX stock decline in price by 69.5% and by 53.5% over the last 12 months. It reached a 52-week high of $14.88 and a low of $1.40.

ESSA’s most recent quarterly results showed its total operating expenses came in at $9.3m, roughly even with the $9.4m achieved in the same period 12 months prior. Research and development and general and administrative costs remained roughly flat.

The company registered a net loss of $8.8m for the period, consistent with the same quarter 12 months prior. ESSA Pharma had cash and cash equivalents of $67.9m at 30 June 2022.

The business does not distribute a dividend to its shareholders.

#EPIX Growth Potential

The company has a significant market opportunity, noting that an estimated 500,000 US residents suffered from prostate cancer in 2020.

The condition is the second most common cause of male cancer deaths, and there are an estimated 248,000 new cases per year, according to the American Cancer Society. Additionally, it caused 31,000 deaths in 2021. 

While antiandrogen treatments for prostate cancer do exist, the company says there is a need for new treatment options as resistance to second-generation antiandrogens is commonplace.

The company says its EPI-7386 differs from all current alternatives as it specifically binds to androgen receptors in a manner that allows it to be effective even against those which are currently resistant to rival antiandrogen treatments.

As such, the company is confident that it is developing a product that provides something different from the competition in an area where there is a significant addressable market.

#EPIX Investment Risks

With any clinical-stage company, the primary risk is that it simply won’t be successful in reaching approval for its products. This is a risk exacerbated by the fact that the company is still in the early stages of clinical development, with its phase 2 trials yet to commence.

This leaves a significant amount of time for regulatory goalposts to be moved or for a competitor to develop a more successful treatment.

Additionally, the business could run out of money in its quest to gain approval. Fortunately for ESSA Pharma, the business appears well funded for roughly two years considering its cash and cash equivalents of around $68m and quarterly losses of roughly $8.9m.

Even so, the business will likely have to seek fresh funding before achieving approval, with there being a possibility that these funding efforts could be unsuccessful or could see shareholders’ holdings diluted. 

#Is EPIX Stock a Good Investment?

ESSA Pharma appears to be a well-funded business that has developed a unique approach to the development of prostate cancer, which affects a major and growing portion of the US population. 

Clinical-stage companies are always an inherently risky investment because there is a possibility that they will never be able to successfully bring their treatment candidates to market.

Additionally, it is worth considering that EPIX is a penny stock and is thus liable to more volatility than equities with a higher price tag.

However, investing in a pharmaceutical stock at such an early stage can net investors eye-watering returns if the business achieves success, though patience is required as backers might be in for the long haul.

Four analysts listed by the Wall Street Journal currently cover the stock, with each of these offering a Buy rating for EPIX. Additionally, they give an average target price of $22.50, compared with the stock’s current price of $4.41.

#If you enjoyed this analysis, why not check out our investigations of DexCom and Matador Resources?

Acuity Brands (NYSE: AYI) reports fiscal 2022 Q4 and full-year results today. The company delivered a strong full-year performance with record net sales delivering operating profit and diluted EPS growth.

Acuity's results beat FactSet analyst estimates. Full-year EPS of $12.83 beat consensus estimates of $12.53, and revenues of $4bn beat consensus of $3.97bn. The AYI share price is up 8% in early trading. 

#What Does Acuity Brands Do?

Acuity Brands, Inc. designs, produces and distributes a full range of indoor and outdoor lighting and control systems. Indeed, it is the largest lighting manufacturer in North America.

The company uses technology to solve problems in spaces and light. Through its two business segments, Acuity Brands Lighting and Lighting Controls (ABL) and the Intelligent Spaces Group (ISG), it designs, manufactures, and commercializes products and services that make a valuable difference in people's lives.

Acuity Brands is a market-leading industrial technology company offering products for commercial and institutional, industrial, infrastructure, and residential applications. Acuity Brands manufactures lighting products worldwide. The company was founded in 2001 and is based in Atlanta, Georgia, with operations across North America, Europe, and Asia. The company is powered by approximately 13,500 dedicated and talented associates.

The team is motivated to make customer-focused lighting efficiencies that are reflected in its business strategy, steadily increasing its market share while delivering superior shareholder returns. Indeed, during the full year of fiscal 2022, Acuity Brands repurchased approximately three million shares of common stock for a total of $512m.

#Q4 Highlights

• Net Sales of $1.11bn

• Increased Net Sales by 12% Y/Y

• Gross profit: $462.5m (up 10% Y/Y)

• Operating profit: $149.6m (up 12.7% Y/Y)

• Diluted EPS: $3.48

• Increased Diluted EPS by 28% Y/Y

• Deployed Additional $107m to Share Repurchases

#Full-Year Highlights

• Net Sales of $4.01bn (up 15.7% Y/Y)

• Increased Net Sales by 16% Y/Y

• Gross profit: $1.7bn (up 13.4% Y/Y)

• Operating profit: $509.7m (up 19.2% Y/Y)

• Increased Diluted EPS by 32% Y/Y

• Deployed Additional $512m to Share Repurchases

Neil Ashe, Chairman, President and CEO of Acuity Brands, Inc., said:

We continued to deliver strong results in the fiscal fourth quarter, concluding what has been a very good fiscal 2022,

We had strong demand across our end markets, and we demonstrated our ability to capture price and drive volume through product vitality and service in both our lighting and spaces businesses throughout this fiscal year.

#How Does Acuity Brands Make Money?

Acuity Brands makes money selling a wide range of lighting products to residential and commercial customers. It has two divisions, its Lighting and Lighting Controls (ABL) division and its Intelligent Spaces Group division (ISG). 

In Q4, Acuity made $162m in adjusted operating profit from ABL and $15m from ISG.

The company sells 19 lighting brands, six lighting control brands, six components brands a two ISG brands. 

#AYI Stock Financials

Over the past year, AYI stock has traded between $142.71 and $224.59. Today it trades at around $173. Year-to-date, the Acuity Brands stock price is down by -25.08%, largely in line with the S&P 500, which is down by -23.31% over the same period.

FactSet analysts have an Overweight rating on AYI stock with a target share price of $193.25.

AYI stock has a price-to-earnings ratio (P/E) of 15.4. Its price-to-book-value (P/BV) is 2.8. which is below the industry benchmark of 3.65. AYI stock comes with a dividend yield of 0.3%.

#Acuity Brands Growth Potential

As part of its longer-term growth strategy Acuity Brands looks to aggressively deploy capital to grow the business and enter attractive new verticals. 

The company achieves growth through the development of innovative new products and services, including lighting, lighting controls, building management systems, and location-aware applications.

The company projects net sales of $4.1bn to $4.3bn in fiscal 2023. It may consider M&A and aims to maintain the dividend.

#AYI Stock Risks

• The company has been battling component challenges via the supply chain and is aiming for more normalized lead times.

• Inflationary pressures remain.

• Container and freight costs fluctuate, they're coming down, but volatility remains.

• Economic strains are weighing on stocks.

#Is AYI Stock a Good Investment?

Acuity Brands (NYSE: AYI) is displaying signs of strength and resilience as economic turmoil rages on. The stock comes with a small dividend, and the company has recently been conducting share buybacks which show its commitment to shareholder gains.

Acuity offers products that deliver value to customers and higher profits to the company, and that continues to be its aim going forward.

The AYI P/E does not appear overly expensive, and the stock offers a lot to like. If the economy is hard hit in the coming year, orders for lighting may not remain a top priority. However, for long-term investors, this could prove a resilient growth stock.

#If you enjoyed our Acuity Brands coverage, you might like our recent Daily Stock Watch articles or IPO coverage.

Enovix Corp (NASDAQ: ENVX) has seen its share price plummet by more than 40% after its latest earnings update left investors disappointed. 

Negligible revenue and a widening loss appears to have spooked some backers, but the battery maker says it spent the quarter improving strategic relationships, shipping free samples and improving manufacturing capabilities.

With lithium-ion batteries potentially an exciting opportunity, it’s well worth examining if ENVX stock is a good investment.

#What Does Enovix Do?

Enovix Corporation designs, develops, and manufactures lithium-ion batteries. The company says its proprietary 3D cell architecture increases energy density and maintains high cycle life.

Enovix is building an advanced silicon-anode lithium-ion battery production facility in the US for volume production. The company's initial goal is to provide designers of category-leading mobile devices with a high-energy battery so they can create more innovative and effective portable products.

The business is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable widespread utilization of renewable energy.

The company was founded in 2007 and is headquartered in Fremont, California.

#ENVX Stock Financials

Revenue for the period came in at just $8,000, a disappointing result when considering that the business made sales of $5.1m in the first half of its financial year. The company stated that the majority of batteries shipped during the quarter were samples that did not generate revenue.

The business says it still expects to achieve revenue of between $6m and $8m across its full year.

With cost of sales from the period coming in at $6.6m and operating expenses amounting to $27.1m, Enovix booked an operational loss of $33.7m. 

The business had cash and cash equivalents of $349m at the end of the period. Enovix does not distribute a dividend to its shareholders.

ENXV stock has fallen by more than 61% across the year to date and by 65% over the last 12 months. During this period it hit highs of $39.48 and lows of $7.26. Currently, the share price is at $10.53.

#ENVX Growth Potential

The fact that the company’s technology can be applied to a broad range of products beyond the EV market is a factor in Enovix’s favour. At the moment, the business is focussed on producing cells for wearable, mobile and computing applications.

It received its first commercial order earlier this year from an unnamed customer which had tested Enovix’s batteries for a year. Another customer focused on small wearable tech has since signed up.

Additionally, the business says it has strengthened relationships with megacap technology companies with multiple portable electronics product applications. Further afield, Enovix says it has active engagements across Asia, including with leading smartphone OEMs in China and major consumer brands in Japan and Korea, including Samsung. 

The business says it had a revenue funnel at the end of the third quarter of $1.4bn, consisting of $1.0bn of engaged opportunities and $423m of active designs and design wins.

The size of the company’s opportunity looks to be growing too, with ResearchandMarkets reporting that the value of the mobile computing battery market is expected to expand from $8.3bn to $15.2bn between 2021 and 2027. It’s also worth noting that the company is building battery technology for the EV market, another rapidly growing segment.

#ENVX Investment Risks

The major concern with Enovix is money and whether the business has the chops to become profitable. At the moment, the company’s operational costs are growing at a far faster rate than revenues, having almost doubled across the year to date compared to the same period in 2021.

That being said, the company has a significant cushion from the almost $350m of cash and cash equivalents it had at the end of its third quarter. However, if costs continue to accelerate this buffer could be eaten away quickly, leading to the company seeking further funding or encountering financial difficulties.

#Is ENVX Stock a Good Investment?

Enovix may have reported a wider than expected loss, but that appears to gloss over the business’ potential. It only reported its first commercial revenues earlier this year and the size of the opportunity on hand is potentially enormous if Enovix can gain a significant foothold in what is a competitive space.

Even so, investing at any business at such an early stage is inherently risky. Revenue acceleration must happen soon for Enovix if the business is to keep up with rapidly increasing operational costs.

The nine analysts covered by the Wall Street Journal all give a Buy rating for ENVX stock, with an average target price of $35.06 per share.

#If you enjoyed this analysis, why not check out our examinations of TuSimple and ESSA Pharma?

In 2021, Mailchimp owner Intuit (NASDAQ: INTU) brought in $9.6bn in revenues and over $2bn in profits. Fast forward a year, and revenues rose 32% to $12.72bn with a similar profit of $2bn in fiscal 2022.

The company owns several popular software systems integral to modern business, and its recent growth trajectory is impressive. However, INTU stock has suffered this year, and the company share price is far below its November 2021 high.

Its debt has rocketed in the past year, and margins are under pressure, so investors will be keen to see how it fares in Q1. Intuit will report its next quarterly update on November 21. FactSet analysts have an EPS consensus of $1.21 and a sales consensus of $2.48bn. EPS guidance lies between $1.14 and $1.20, while sales guidance comes between $2.47bn and $2.51bn.

#What is Intuit?

Intuit's popular software offerings include QuickBooks, Credit Karma, TurboTax, Mailchimp and Mint.

Intuit Inc. develops and markets business and financial management software solutions for small and medium-sized businesses, financial institutions, consumers, and accounting professionals. The company provides business management, payroll processing, personal finance, tax preparation, and filing software solutions. Intuit serves customers worldwide.

#Q4 and Full-Year Update

For the full 2022 fiscal year, including the addition of Mailchimp beginning November 1, Intuit:

• Grew total revenue to $12.7bn, up 32% Y/Y, including 8 points from the addition of Mailchimp.

• Increased combined Platform revenue, which includes the Small Business and Self-Employed Group Online Ecosystem, TurboTax Online and Credit Karma, by 45% to $9.6bn. This includes 11 points from the addition of Mailchimp.

• Grew Small Business and Self-Employed Group revenue by 38% and Online Ecosystem revenue by 61%. Excluding Mailchimp revenue of $762m, Small Business and Self-Employed Group revenue grew by 22%, and Online Ecosystem revenue grew by 34%.

• Grew Consumer Group revenue by 10% to $3.9bn.

• Increased Credit Karma revenue to $1.8bn.

• Reported GAAP operating income of $2.6bn, up 3%.

• Reported Non-GAAP operating income of $4.5bn, up 29%.

• Reported GAAP earnings per share declined by 4%, and non-GAAP earnings per share grew by 22%.

For Q4, Intuit:

• Reported total revenue of $2.4bn, down 6%, reflecting the earlier IRS tax filing deadline this year, partially offset by the addition of Mailchimp. Excluding Mailchimp, total revenue declined by 16%.

• Increased Small Business and Self-Employed Group revenue by 41% to $1.8bn and Online Ecosystem revenue by 66%. Excluding Mailchimp revenue of $265 million, Small Business and Self-Employed Group revenue grew by 20%, and Online Ecosystem revenue grew by 32%.

• Grew Credit Karma revenue by 17% to $475 million.

• Reported Consumer Group revenue of $145 million, compared to $852 million in the prior year, reflecting the earlier tax filing deadline this year.

Sasan Goodarzi, Intuit's CEO, said:

We had a very strong fourth quarter, ending the year with momentum. We're more confident than ever in our long-term business strategy as we power prosperity around the world,

Our platform and offerings are mission-critical for consumers and small businesses, and we are proud that Intuit is the platform of choice for over 100 million customers.

#How Does Intuit Make Money?

Intuit enjoys multiple revenue streams, from software licensing and updates to software subscriptions, referrals, and advertising.

The company's leading range of product offerings allows scope for cross-selling to help it scale.

#INTU Stock Financial Metrics

Intuit currently has a $113.07bn market cap.

Over the past year, INTU stock has traded between $339.36 and $716.86. Today it trades at around $417.18. Year-to-date, the Intuit stock price is down -33.9%, while the S&P 500 is down -21.76% over the same period. 

INTU stock has a price-to-earnings ratio (P/E) of 57.57, and its forward P/E is 29. Its price-to-book-value (P/BV) is 7.18. INTU stock also comes with a dividend yield of 0.75%.

Since 2009, the company has gone from strength to strength, with revenue growth of 11.4%. This accelerated from the onset of the pandemic, when interest in digital adoption grew, too, particularly in smaller businesses.

While growth appeals to investors, Intuit's aggressive M&A strategy has led the company to become less shareholder-friendly as it issued more shares through employee compensation and increased its debt. EBIT margins were averaging 27%, but this slipped to 20% in 2022.

The debt increase is massive. In 2019, INTU's long-term debt sat at $386m. By 2022 it reached $6.9bn. 

Cash soared to $7bn in 2020 but slipped to $3.2bn by 2022.

The company anticipates revenues of $14.48bn to $14.7bn in 2023, which aligns with its pre-pandemic growth rate. 

In recent weeks various analysts have adjusted their outlook on Intuit. Oppenheimer reiterated its $516 target, while JPMorgan Chase & Co downgraded INTU stock from Overweight to neutral with a target of $360.

Evercore ISI lowered its price target from $601 to $505. Meanwhile, Deutsche Bank increased its target INTU share price from $525 to $560.

Overall, FactSet analysts have a consensus Overweight rating on INTU stock with a target share price of $521.73.

#INTU Growth Potential

Intuit is excited about its Mailchimp acquisition which it sees as central to its ongoing growth strategy.

James Alexander Chriss, Executive VP & General Manager-Small Business & Self-Employed Group, Intuit, Inc, stated:

With Mailchimp, we have a low compliance, universally scalable, and proven global product that solves customers' number one problem of getting customers.

The company will use Mailchimp to entice global customers into its ecosystem.

From a data perspective, Intuit has insight into valuable consumer data from its QuickBooks integrations. This includes consumer spending patterns and employee hiring rates. Providing it puts this knowledge to work, it could streamline when necessary and take risks ahead of the curve. This gives it added value in the eyes of the shareholder.

Furthermore, this inside knowledge gives it confidence in lending to small businesses to get them up and running on their marketing journey to acquire more business and a positive return on investment.

Intuit also intends to bring its full QuickBooks offering into Canada, the UK and Australia, where Intuit is already established.

#INTU Investment Risks

• The company has racked up considerable debt, and when it's time to renew its loans, this could come at higher interest rates.

• Inflation is affecting all businesses to a degree, and Intuit is vulnerable.

• Finance is a highly competitive environment, and as consumer confidence wanes, only the most trusted will survive. 

• With the US believed to be in a recession, spending is likely to slow.

• The company has diluted its shares with share-based compensation, which appears to inflate its results.

• Tech stocks have fallen out of favor and are subject to increased volatility.

#Is INTU Stock a Good Investment?

Intuit is a good company with a solid offering, supporting many small businesses. Nevertheless, as the global economy battles through the next few months, Intuit could be vulnerable to several risks.

The share price remains overvalued, and investors will likely remain cautious as volatility is expected to continue.

#Want to read more about trending stocks? Read our analysis to discover why Nextplay and Intuitive Surgical's share prices jumped last week!